Navigation Links
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Date:12/12/2011

balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisLocated in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

References

  1. Hughes TP, Lipton JH, Leber B et al. Complete Molecular Response (CMR) Rate With Nilotinib in Patients (pts) With Chronic Myeloid Leukemia in Chronic Chase (CML-
    '/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... health and safety of Canadians is our government,s highest priority.  Our ... at its disposal to help ensure that the drugs Canadians need ... end, Health Canada has taken decisive ... of all drug products from three plants in ... Pharmachem India Pvt Ltd , Apotex Research Private Limited ...
(Date:9/30/2014)... 2014  Tasly Pharmaceuticals, Inc., the world,s leader ... today the launch of Deepure. Deepure ... men and women concerned with supporting their overall ... age while helping keep their health care cost ... herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources ... devices in Brazil , ... China (BRIC) will see robust ... are increasingly favored over surgical procedures. Although revenues will ... resources, reimbursement challenges, prolonged device approval times and demand ...
Breaking Medicine Technology:Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3
(Date:10/1/2014)... October 01, 2014 Lifeinsurance-policy.com has ... the best life insurance prices for smokers. , Smoking ... insurance premiums. Comparing quotes is the best method to ... quotes for customers who need coverage. , Whole ... duration of the policy. Since the coverage is permanent, ...
(Date:10/1/2014)... October 01, 2014 Join the more than ... Disorder Treatment Center’s first ever charity golf tournament to benefit ... with eating disorders who cannot afford treatment. The tournament will ... in Eureka, Mo. , The day-long event starts with ... reception and award dinner will begin at 5 p.m. and ...
(Date:10/1/2014)... Diet Doc understands that many of their ... and their dieting attempts could be easily sabotaged by the ... diet treatments into their programs as a way to ... and effective weight loss results, it also allows patients to ... maintain their weight for the future. , Earlier versions of ...
(Date:10/1/2014)... Dar, Ethiopia, at the occasion of the Leishmaniasis ... 150 African and international leishmaniasis experts, results of ... efficacy monitoring plan, carried out by MSF, ... and Ethiopia, were presented to key decision makers ... of kala-azar with the combination of Sodium Stibogluconate ...
(Date:10/1/2014)... 01, 2014 Today marks the final ... Art Institute in Oxnard and Woodland Hills, Calif., is ... mouth rehabilitation training. , “Speaking to this group of ... procedures to get the help and care they deserve,” ... repairing previous dental work, providing cosmetic dentistry, correcting bite ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5
... , , Patient-Based Record ... , MADISON, N.J., July 20 MedPlus, the ... DGX ), today announced that NYCLIX is now sharing ... New York City using the company,s Centergy(TM) suite of ...
... , SEOUL, South Korea, July 20 ... to announce that its wholly owned subsidiary, VASKA, a ... institutional, and consumer markets, has successfully turned the first major commercial ... Royal Laundry of South San Francisco is the largest ...
... , , ... campaign in support of bipartisan health care reform. , ... Plans (AHIP), "Illness", calls for fixing health care to make sure all Americans ... , "Illness doesn,t care where you live. . .or if ...
... , , , ... Oldsmar, Fla., July 20 /PRNewswire-FirstCall/ -- Women today have a number ... of their families. Banking stem cells found in menstrual blood is one way ... injuries. Menstrual blood has been shown to contain self-renewing stem cells that may ...
... Calif., July 20 SynergEyes, Inc., the high Dk ... lens design for keratoconus patients. ClearKone(TM) is a revolutionary ... of the hybrid platform, providing superior visual acuity, centration, ... to vault the predominant irregularities of the keratoconic cornea, ...
... , , BRIDGEWATER, ... pooled results from two Phase 3 studies (DUET-1 and ... non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) ... copies/mL) while taking INTELENCE(TM) (etravirine) tablets plus background regimen ...
Cached Medicine News:Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 2Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 3Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 4Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Health Plans Return to Airwaves in Support of Bipartisan Reform 2Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 2Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 3Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 4Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 5Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 3Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 2Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 3Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 4Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 5Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 6
... magnification and increased stereopsis, the ... for detailed visualization to the ... is ideal for vitrectomy in ... in proliferative vitreoretinopathy extending to ...
... Volks Reinverting Operating Lens System® ... advanced wide angle viewing system ... Its unique single-element prism design, ... wide-field viewing capability have made ...
... The new Volk Blumenthal Suturelysis ... flap sutures, enabling cutting sutures which, ... relatively inaccessible. The lens provides localized ... of the suture 2-3 times, resulting ...
... Laser capsulotomy procedures are now greatly improved ... Lens. This new lens promotes precise and ... bag. Computer optimized for enhanced viewing and ... new aspheric design comes standard with LaserWindow ...
Medicine Products: